BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)
1.590
-0.230
(-12.64%)
Streaming Delayed Price
Updated: 12:13 PM EDT, Apr 4, 2025
Add to My Watchlist
All News about BioXcel Therapeutics, Inc. - Common Stock

Expert Ratings for BioXcel Therapeutics
November 15, 2023
Via Benzinga



Recap: BioXcel Therapeutics Q3 Earnings
November 14, 2023
Via Benzinga

Earnings Outlook For BioXcel Therapeutics
November 13, 2023
Via Benzinga

Where BioXcel Therapeutics Stands With Analysts
September 08, 2023
Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 14, 2023
Via Benzinga

BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy Trial
November 08, 2023
Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session
October 30, 2023
Via Benzinga

Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results
October 25, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities


12 Health Care Stocks Moving In Wednesday's Intraday Session
October 25, 2023
Via Benzinga



Nasdaq Down 1.5%; Microsoft Posts Upbeat Results
October 25, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities


12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 25, 2023
Via Benzinga



Why Shares of BioXcel Therapeutics Fell This Week
September 28, 2023
Via The Motley Fool
Topics
Workforce
Exposures
Layoff

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
October 05, 2023
Via Benzinga
NASDAQ: BTAI Investor Alert: Deadline on September 5, 2023 in Lawsuit Against BioXcel Therapeutics, Inc.
September 05, 2023
Via SBWire
Topics
Lawsuit


Via NewMediaWire
Topics
Lawsuit




Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free